Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
- Alternative title
-
Untersuchung der Proteinexpression der Urokinase (uPA), des Plasminogen-Aktivator-Inhibitors Typ 1 (PAI-1) und des Urokinase-Rezeptors (uPAR) mittels Immunhistochemie im triple-negativen Mammakarzinom (TNBC)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
München, Technische Universität München, Dissertation, 2020
- Keyword
-
Breast--Cancer
Expression
Plasminogen
Urokinase
Immunohistochemistry
- Event
-
Veröffentlichung
- (where)
-
München
- (who)
-
Universitätsbibliothek der TU München
- (when)
-
2020
- Creator
-
Kendziora, Elena Stephanie
- Contributor
-
Magdolen, Viktor
Weichert, Wilko
Magdolen, Viktor
- URN
-
urn:nbn:de:bvb:91-diss-20200128-1485545-1-8
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:44 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kendziora, Elena Stephanie
- Magdolen, Viktor
- Weichert, Wilko
- Universitätsbibliothek der TU München
Time of origin
- 2020
Other Objects (12)
Urokinase-type plasminogen activator receptor in vascular calcification
Die Bedeutung der Plasminogenaktivatoren tissue-type-plasminogen activator und urokinase-type plasminogen activator für den Ischämie-Reperfusionsschaden
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Regulation of the human urokinase type plasminogen activator receptor gene
Einfluss von Biopsie-, Aufarbeitungs- und Asservierungsbedingungen auf den Nachweis von urokinase type plasminogen activator (uPA) und plasminogen activator inhibitor-1 (PAI-1) beim Mammakarzinom
The role of urokinase-type plasminogen activator (uPA) in proliferation and signal transduction within breast cancer cells
Urokinase-type plasminogen activator (uPA) als Mediator der durch tissue inhibitor of metalloproteinases-1 (TIMP-1) induzierten Lebermetastasierung
Soluble urokinase plasminogen activator receptor (supar) concentrations are elevated in patients with neuroendocrine malignancies
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression
Influence of delivery on plasminogen activator inhibitor activity
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis
Mechanism for cAMP-mediated induction of the urokinase plasminogen activator gene in kidney epithelial cells
Urokinase-type plasminogen activator receptor in vascular calcification
Die Bedeutung der Plasminogenaktivatoren tissue-type-plasminogen activator und urokinase-type plasminogen activator für den Ischämie-Reperfusionsschaden
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Regulation of the human urokinase type plasminogen activator receptor gene
Einfluss von Biopsie-, Aufarbeitungs- und Asservierungsbedingungen auf den Nachweis von urokinase type plasminogen activator (uPA) und plasminogen activator inhibitor-1 (PAI-1) beim Mammakarzinom
The role of urokinase-type plasminogen activator (uPA) in proliferation and signal transduction within breast cancer cells
Urokinase-type plasminogen activator (uPA) als Mediator der durch tissue inhibitor of metalloproteinases-1 (TIMP-1) induzierten Lebermetastasierung
Soluble urokinase plasminogen activator receptor (supar) concentrations are elevated in patients with neuroendocrine malignancies
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression
Influence of delivery on plasminogen activator inhibitor activity
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis
Mechanism for cAMP-mediated induction of the urokinase plasminogen activator gene in kidney epithelial cells
Urokinase-type plasminogen activator receptor in vascular calcification
Die Bedeutung der Plasminogenaktivatoren tissue-type-plasminogen activator und urokinase-type plasminogen activator für den Ischämie-Reperfusionsschaden
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Regulation of the human urokinase type plasminogen activator receptor gene
Einfluss von Biopsie-, Aufarbeitungs- und Asservierungsbedingungen auf den Nachweis von urokinase type plasminogen activator (uPA) und plasminogen activator inhibitor-1 (PAI-1) beim Mammakarzinom
The role of urokinase-type plasminogen activator (uPA) in proliferation and signal transduction within breast cancer cells
Urokinase-type plasminogen activator (uPA) als Mediator der durch tissue inhibitor of metalloproteinases-1 (TIMP-1) induzierten Lebermetastasierung
Soluble urokinase plasminogen activator receptor (supar) concentrations are elevated in patients with neuroendocrine malignancies
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression
Influence of delivery on plasminogen activator inhibitor activity
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis